# UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder

> **NCT03933410** · PHASE2 · TERMINATED · sponsor: **Kaleido Biosciences** · enrollment: 13 (actual)

## Conditions studied

- Urea Cycle Disorder

## Interventions

- **DRUG:** KB195

## Key facts

- **NCT ID:** NCT03933410
- **Lead sponsor:** Kaleido Biosciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-09-17
- **Primary completion:** 2021-02-02
- **Final completion:** 2021-03-02
- **Target enrollment:** 13 (ACTUAL)
- **Why stopped:** Kaleido Biosciences, Inc. closed the K020-218 trial due to business reasons, and not due to any safety concerns.
- **Last updated:** 2022-01-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03933410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03933410, "UNLOCKED: A Phase 2, Open-label Trial With KB195 in Subjects With a Urea Cycle Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03933410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*